| US 7,488,739 B2 | ||
| Quinolone derivative or salt thereof | ||
| Susumu Watanuki, Chuo-ku (Japan); Yuji Koga, Chuo-ku (Japan); Hiroyuki Moritomo, Chuo-ku (Japan); Issei Tsukamoto, Chuo-ku (Japan); Daisuke Kaga, Chuo-ku (Japan); Takao Okuda, Chuo-ku (Japan); Fukushi Hirayama, Chuo-ku (Japan); Yumiko Moritani, Chuo-ku (Japan); and Jun Takasaki, Chuo-ku (Japan) | ||
| Assigned to Astellas Pharma Inc., Tokyo (Japan) | ||
| Appl. No. 10/562,128 PCT Filed Jul. 22, 2004, PCT No. PCT/JP2004/010781 § 371(c)(1), (2), (4) Date Dec. 23, 2005, PCT Pub. No. WO2005/009971, PCT Pub. Date Feb. 03, 2005. |
||
| Claims priority of application No. 2003-278852 (JP), filed on Jul. 24, 2003. | ||
| Prior Publication US 2006/0148806 A1, Jul. 06, 2006 | ||
| Int. Cl. A61K 31/47 (2006.01); C07D 215/233 (2006.01); C07D 237/28 (2006.01); C07D 407/02 (2006.01) | ||
| U.S. Cl. 514—312 [514/248; 514/300; 546/123; 546/156; 544/235; 544/236] | 14 Claims |
1. A platelet aggregation inhibitor comprising a quinolone derivative represented by the formula (I) or a pharmaceutically
acceptable salt thereof as an active ingredient:
 X: C—R7 or N;
Y: C—R6 or N;
R11: —H;
R12: a lower alkyl which is substituted;
R2: a lower alkyl or a cycloalkyl;
R3: a halogen;
R4: a cycloalkyl;
R5:—H;
R6: —H;
R7: —H.
|